No Data
No Data
[IPO Monthly Report] The heat of the Hong Kong IPO market in October shows no signs of decreasing. Karot super subscription 1346 times, CR Beverage may become the annual "Frozen Capital King".
In September, Midea Group Co., Ltd (00300) raised 35.7 billion yuan, becoming the largest fundraising in the Hong Kong stock market since February 2021, the largest in Asia in the first three quarters of 2024, and the second largest globally in 2024. Charles Li Xiaojia, CEO of HKEX, said: "Recently, the Hong Kong Stock Exchange welcomed the largest new stock listing in Asia and the second largest globally this year. Refinancing activities have also been very active, demonstrating the depth and attractiveness of our market. The number of new stock listing applications further consolidates Hong Kong's position as the preferred new stock fundraising center in Asia. In addition, Alibaba has converted to a dual primary listing and was subsequently included in the Stock Connect."
Taimai Technology (02576): Stable pricing action, end of stable pricing period, and expiration of excess rights issue.
TaiMei Medical Technology (02576) announced that the stable price period for the global offering will expire on November 2, 2024...
Hong Kong stock abnormal fluctuation | More Medical Technology (02576) fell by over 11% again, with the stock price nearly halved after 5 days of listing. The company has accumulated losses of over 1.2 billion yuan in three years.
Taimai Medical Technology (02576) fell by over 11% again. Since its listing on October 8th, the stock has been declining for 5 trading days in a row, and the current stock price is close to halving compared to the HK$13 IPO price.
"The first stock of medical SaaS" Taimei Medical Technology (2576.HK) went public, adding a new star to the life science digitalization track.
Recently, many companies have submitted batches of documents, and IPO projects have also shown a significant acceleration, including high-quality investment targets that the market is looking forward to. On October 8th, 'the first stock of medical SaaS (software as a service)' TaiMei Medical Technology officially went public. As the first Hong Kong stock listed after the National Day holiday, and with endorsements from star-studded institutions such as Hillhouse Capital and Tencent, TaiMei Medical Technology has attracted the attention of many investors. 1. Drawing lessons from others: TaiMei Medical Technology, formerly underestimated by the US stock market, focuses on digital solutions in the life science sector of medicine and medical instruments industry, by designing and providing industry-specific.
The stock price has fallen by nearly 40% in the first two days of listing. TaiMei Medical Technology (02576) continues to struggle with losses, finding it difficult to sell its products.
Both recently listed on IPO, Taimei Medical Technology (02576) has become the "background board" of the hot IPO market in Hong Kong.
Express News | TaiMei Medical went public and immediately fell by 30%: The common problem of SaaS remains unsolved, revenue growth rate has dropped to single digits, continuous losses and customer churn.